Catalent Belgium SA – FDA 483
An FDA inspection of Catalent Belgium SA revealed significant deficiencies in their manufacturing processes for sterile drug products. Observations included a lack of established procedures for handling media fill failures, inadequate adherence to good documentation practices by the quality control unit, and insufficient controls over computer systems allowing unauthorized data manipulation. Additionally, the firm failed to establish the accuracy and reproducibility of certain analytical test methods.
- Company
- Catalent Belgium SA
- Product type
- drugs
ID · 8c3c7fa7-4d02-435e-bfa7-eca8c01018fd
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.